ABSI Absci Corporation
$11.88▲ +12.39%
Healthcare
Other
After hours
$11.80▼ -0.67%
Oct 28, 7:58 PM ET
Volume 5.81M
Avg Volume (10D) 3.62M
Key Metrics & Fundamentals
Market Cap
$2.04B
P/E Ratio
–
Div Yield
0.00%
52W Range
2.24 - 12.06
% vs 50 MA
26.01%
% vs 200 MA
85.44%
RSI-14
64.3
MACD Histogram
+0.2000
Beta (1Y vs SPY)
3.48
Free Cash Flow
-$27.57M
Gross Rev
$318,000
Gross Profit
$318,000
EBITDA
-$30.47M
COGS
–
Operating Exp
$34.48M
Operating Income
-$34.16M
EBIT
-$34.16M
Pretax Income
-$33.17M
Net Income
-$33.21M
EPS (Diluted)
-0.21
Price & Volume History
Loading chart…
Recent News
Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally
TIKR · Oct 28, 2026 12:11 PM ET
Absci to Participate in Upcoming Investor Conferences
GlobeNewswire · Oct 27, 2026 8:00 AM ET
Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?
Simply Wall St. · Oct 24, 2026 3:08 PM ET
Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop
Simply Wall St. · Oct 16, 2026 7:11 PM ET
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
GlobeNewswire · Oct 13, 2026 8:00 AM ET
Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?
Simply Wall St. · Oct 7, 2026 7:17 PM ET
Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
MT Newswires · Sep 24, 2026 8:18 AM ET
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
GlobeNewswire · Sep 24, 2026 8:00 AM ET
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Simply Wall St. · Sep 22, 2026 4:19 AM ET
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
MarketBeat · Sep 20, 2026 9:02 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ABSI's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.